Ulta's Q4 Demand Strength Masks Lingering Profitability and Cash Flow Concerns

What happened

Ulta Beauty reported Q4 comparable sales growth of 5.8% and revenue of $3.9 billion, reinforcing narratives of resilient beauty demand as shoppers stay value-focused. However, the DeepValue master report highlights that this top-line performance conceals significant pressures on profitability, with SG&A expenses deleveraging to 29.4% of sales in Q3 FY2025 due to labor costs and cloud software amortization. Inventories have swelled to $2.7 billion, driving variable-rate revolver borrowings to $552 million and straining cash conversion, as evidenced by declining operating cash flow. Additional risks loom from the impending August 2026 conclusion of the Target partnership and the integration of Space NK, which carries $382 million in goodwill. Thus, while demand remains robust, Ulta's ability to translate sales into sustainable earnings and free cash flow is critically contested.

Implication

The Q4 sales strength supports Ulta's base case of steady comps, but investors must monitor whether SG&A stabilizes below 28.0% to confirm operating leverage and avoid the bear scenario of margin compression below 11.5%. Inventory levels above $2.7 billion and revolver borrowings exceeding $500 million by May 2026 would signal deteriorating cash discipline, potentially driving the stock towards the $560 bear valuation. Near-term catalysts include the next quarterly report showing SG&A re-leverage and inventory normalization, without which the stock may struggle to exceed the $750 trim level. Long-term, the Target partnership unwind and Space NK integration failures pose material risks to sales retention and capital allocation, with early warnings in 'other revenue' declines. Therefore, prudent investors should wait for evidence of improved cash conversion and margin sustainability before considering entry above $580 or trimming positions.

Thesis delta

The Q4 sales data confirms the demand resilience already priced into Ulta's stock, but it does not address the core thesis challenges of SG&A deleverage and working capital intensity. Thus, the investment thesis remains unchanged: a WAIT rating is justified until upcoming quarters demonstrate tangible progress on profit retention and cash conversion, with no shift in the near-term outlook.